The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .
Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia
Summary The effects of bezafibrate 400 mg/day ( slow release formulation ) on plasma lipids/lipoproteins and on selected haemostatic parameters were evaluated in a double blind cross-over study in patients with Type IIb and IV hyperlipoproteinaemia .  Placebo treatment did not influence any of those parameters , but the drug significantly reduced plasma triglycerides ( −45 % ) and VLDL cholesterol , as well as causing a 12 % fall in total cholesterol and a 20 % increase in HDL cholesterol . Apo AI levels were significantly increased following bezafibrate and Apo B was reduced by about 20 % . In addition to changes in the plasma lipid profile , bezafibrate reduced the sensitivity of platelets to the aggregatory effect of collagen , with no effect on TXB2 production . Fibrinogen levels  after bezafibrate treatment were significantly lowered , the effect being more marked in patients with hyperfibrinogenaemia  . Bezafibrate did not influence the plasma fibrinolytic profile . It is concluded that bezafibrate , besides its beneficial effects on the plasma lipoprotein profile , can exert beneficial changes on specific haemostatic parameters
The estimated effects of fibrate therapy on plasma concentration and activity of PAI-1 were independent of treatment duration and changes in plasma triglyceride levels in the meta-regression analysis .
This meta- analysis of RCTs suggested that fibrate therapy does not reduce plasma concentration or activity of PAI-I. The putative benefits of fibrate therapy in patients with cardiovascular disease appear to be exerted via mechanisms independent of effects on PAI-1
OBJECTIVE The aim of this systematic review was to perform a meta- analysis of r and omized controlled trials ( RCTs ) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 ( PAI-1 ) .